GT Medical Technologies
Summary active Updated Jun 11, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
GT Medical Technologies is a Tempe, Arizona-based medical device company commercializing GammaTile, an FDA-cleared bioresorbable implant placed at the time of brain tumor removal surgery to deliver immediate radiation to the resection site 12. At the American Society of Clinical Oncology (ASCO) 2026 meeting, GT Medical presented data from its ROADS randomized controlled trial showing that GammaTile reduced the risk of tumor recurrence and death at 12 months by 93% and 41%, respectively, compared with standard of care 1. Per Langoe serves as Chief Executive Officer and James Leech as Chief Financial & Strategy Officer 1. Proceeds from the round will support the BRIDGES randomized controlled trial in patients with newly diagnosed glioblastomas, as well as commercial and operational expansion 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-09 | Series E | $100M | Viking Global Investors | MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, FemHealth Ventures 123 |
What Investors Say
“GT Medical Technologies’ technology has demonstrated profound clinical impact, and we look forward to supporting the GT Medical Technologies team in improving the treatment algorithm for patients with resectable brain tumors.” — Jason Rostovsky, Principal, Viking Global Investors 13
What Founders Say
“This financing is validation of GammaTile’s potential to be a standard of care treatment for operable brain tumors and will accelerate our ability to bring this important therapy to even more patients.” — Per Langoe, CEO, GT Medical Technologies 13
Sources
-
PR Newswire, “GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors,” June 9, 2026. https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html↩↩↩↩↩↩↩
-
MedTech Dive, “GT Medical raises $100M for brain tumor tech after clinical trial success,” June 2026. https://www.medtechdive.com/news/gt-medical-raises-100m-for-brain-tumor-tech-after-clinical-trial-success/822536/↩↩
-
BioSpace, “GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing,” June 2026. https://www.biospace.com/press-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors↩↩↩